|
Patient and tumor characteristics |
||
| Clinical factors |
ER negative (n = 65) |
ER positive (n = 65) |
|
|
||
| Menopausal status |
||
| Premenopause |
35 |
35 |
| Postmenopause |
30 |
30 |
| T stage |
||
| T1c |
24 |
24 |
| T2 |
37 |
37 |
| T3 |
4 |
4 |
| N stage |
||
| N0 |
38 |
38 |
| N1 |
26 |
27 |
| N2 |
1 |
0 |
| M stage |
||
| M0 |
65 |
65 |
| M1 |
0 |
0 |
| AJCC stage |
||
| I |
17 |
17 |
| IIa |
28 |
28 |
| IIb |
16 |
16 |
| IIIa |
4 |
4 |
| IV |
0 |
0 |
| HER2/neu |
14/51 (27%) |
15/56 (27%) |
|
|
||
| Total |
65 |
65 |
|
ER, estrogen receptor; HER, human epidermal growth factor receptor. | ||
Sunami et al. Breast Cancer Research 2008 10:R46 doi:10.1186/bcr2098 |
||